Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TERT | O14746 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7847021 | 0.95 | SMN1; SMN2 (0.90) | SMN1; SMN2TERTMAPTPKMRAB9A | |
| SCHEMBL16972520 | 0.93 | SMN1; SMN2 (0.87) | SMN1; SMN2TERTMAPTPKMRAB9A | |
| SCHEMBL6365491 | 0.90 | SMN1; SMN2 (0.82) | SMN1; SMN2TERTMAPTPKMRAB9A | |
| SCHEMBL6442004 | 0.88 | SMN1; SMN2 (0.78) | SMN1; SMN2TERTMAPTPKMMEN1 | |
| SCHEMBL1115 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2TERTMAPTPKMRAB9A | |
| SCHEMBL8055630 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2TERTMAPTPKMMEN1 | |
| SCHEMBL17390148 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTPKMRAB9ALMNA | |
| SCHEMBL13743000 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2TERTMAPTPKMMEN1 | |
| SCHEMBL1295 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2TERTMAPTMEN1KMT2A | |
| SCHEMBL8205572 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTPKMLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117110505-A | Detection method and quality control limit of genotoxic impurities in sildenafil citrate | 江苏亚邦爱普森药业有限公司 | 2023-11-24 | — | — | CN | claimed |
| EP-3099689-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2022-01-26 | — | — | EP | claimed |
| CN-112608317-A | Sildenafil citrate preparation method | 植恩生物技术股份有限公司 | 2021-04-06 | — | — | CN | claimed |
| CN-111005033-B | Electro-reduction preparation method of sildenafil intermediate | 浙江大学 | 2020-10-16 | — | — | CN | claimed |
| CN-111005033-A | Electro-reduction preparation method of sildenafil intermediate | 浙江大学 | 2020-04-14 | — | — | CN | claimed |
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-10 | — | — | US | claimed |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-03-09 | — | — | US | claimed |
| EP-3099689-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2016-12-07 | — | — | EP | claimed |
| WO-2015114647-A1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | claimed |
| EP-1077214-A1 | An improved process for preparing a pyrazolopyrimidinone derivative | Orchid Chemicals & Pharmaceuticals Ltd. (IN) | 2001-02-21 | — | — | EP | claimed |
| EP-4563579-A1 | MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-118176183-A | HIF-2 alpha inhibitors and methods of use thereof | 艾库斯生物科学有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024071392-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIA, AND MAGNETIC RECORDING MEDIUM | 株式会社レゾナック | 2024-04-04 | — | — | WO | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-117110505-A | Detection method and quality control limit of genotoxic impurities in sildenafil citrate | 江苏亚邦爱普森药业有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0526004-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1993-02-03 | — | — | EP | disclosed |
| CN-1068329-A | Pyrazolopyrimidinoneantianginal antianginal agents | PFIZER (US) | 1993-01-27 | — | — | CN | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
| CN-1057464-A | Pyrazolopyrimidinoneantianginal antianginal agents | PFIZER (US) | 1992-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017511-B2 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1902/4885TERT 4032/4885MAPT 3388/4885 |
| US-20170066771-A1 | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof | PDE5A, PDE3A, PDE3B | SMN1; SMN2 1902/4885TERT 4032/4885MAPT 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.